Next 10 |
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...
2024-05-20 12:53:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genprex (NASDAQ: GNPX ) just reported results for the first quarter of 2024. Genprex reported earnings per share of -$3.69. This was above the analyst estimate for EPS of ...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR Newswire Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNews...
2024-05-09 03:45:26 ET More on Genprex Seeking Alpha’s Quant Rating on Genprex Historical earnings data for Genprex Financial information for Genprex Read the full article on Seeking Alpha For further details see: Genprex co-founder, CEO pa...
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" o...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating at two conferences during May. According to the announcement, Genprex CFO Ryan Confer will be presenting at the Sidoti Microcap...
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences PR Newswire AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developin...
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Compelling Data Validates the Potential...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...